Optimum Dose of rhCC10 for Lung Protection in IRDS
Optimum Dose of rhCC10 for Lung Protection in IRDS
批准号:
6344251
负责人:
APRILE L PILON
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-02 至 2002-12-31
关键词:
biotherapeutic agent cytoprotection dosage drug administration routes drug screening /evaluation glycoproteins histochemistry /cytochemistry newborn animals phospholipase inhibitor pulmonary surfactants recombinant proteins respiratory disorder chemotherapy respiratory distress syndrome of newborn respiratory epithelium respiratory pharmacology sheep
中文摘要
描述(扫描自申请人描述):拟进行的研究
英文摘要
DESCRIPTION (Scanned from the applicant's description): The proposed study
involves an evaluation of the dose response to recombinant human CC10 in the
preterm lamb, a surfactant-dependent model of neonatal/infant respiratory
distress syndrome (IRDS). The preterm lamb model was used in the clinical
development of artificial surfactants for the treatment of IRDS. CC10 is
normally secreted by the Clara cells of the tracheal and bronchial epithelia of
the mature lung. It is abundant in the extracellular fluids of the lungs and is
a natural component of endogenous surfactant. Analogous to surfactant, CC10 is
not present in the lungs of preterm babies. Preliminary results indicate that
CC10 is, in fact, essential to normal lung function, and that a replacement
strategy with rhCC10 may be effective in reducing pulmonary inflammation and
incidence of chronic lung disease (CLD) in premature babies treated for
respiratory distress. The safety of administration of high doses of rhCC10 has
already been established in pre-clinical studies in newborn piglets. A
controlled study to optimize the dose response for maximal lung protection and
define the clinical parameters to measure efficacy of rhCC10, administered in
conjunction with artificial surfactant, in a preterm surfactant dependent model
of IRDS, is now proposed.
PROPOSED COMMERCIAL APPLICATION:
CC10 is currently in Phase I of clinical development of rhCC10 for the prevention of neonatal broncho-pulmonary dysplasia. This study is important in designing effective dosing strategies
for further clinical development. According to recent estimates, approximately 90,000
premature babies are born in the U.S. each year. Of those, about 50,000 will have infant
respiratory distress syndrome (IRDS) AND 20,000 of those babies with IRDs will develop
BPD or some form of chronic lung disease. The annual cost of treating these babies in the
first three months of life is about $200,000 each for an annual expense of a minimum of
$4 billion. Many of these babies continue to have respiratory problems throughout childhood
and the cost of this continued care have not been included in the $4 billion/year estimate.
Recombinant human CC10 has the potential to prevent this disease and reduce the annual
economic burden of caring for these children. RhCC10 may also be important in treating
many pediatric and adult respiratory diseases as well.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction
-
批准号:10602077
-
项目类别:
-
资助金额:$26.07万
-
财政年份:2023
-
负责人:APRILE L PILON
-
依托单位:
Role of Secretoglobin 1A1 Protein in COVID-19-induced Thrombosis
-
批准号:10255855
-
项目类别:
-
资助金额:$25.65万
-
财政年份:2021
-
负责人:APRILE L PILON
-
依托单位:
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
-
批准号:7325568
-
项目类别:
-
资助金额:$16.95万
-
财政年份:2007
-
负责人:APRILE L PILON
-
依托单位:
Development of Novel Bioprocess Platform for Rapid, Economical Production of Pept
-
批准号:7848987
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2007
-
负责人:APRILE L PILON
-
依托单位:
Recombinant CC10 for treatment of meconium aspiration
-
批准号:6645573
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2003
-
负责人:APRILE L PILON
-
依托单位:
RECOMBINANT HUMAN CC10 AND NOTCH-1 ANTAGONIST IN NSCLC
-
批准号:6143475
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2000
-
负责人:APRILE L PILON
-
依托单位:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
-
批准号:2616435
-
项目类别:
-
资助金额:$9.79万
-
财政年份:1998
-
负责人:APRILE L PILON
-
依托单位:
RECOMBINANT HUMAN CC10 FOR PREVENTION OF NEONATAL BPD
-
批准号:6017162
-
项目类别:
-
资助金额:$74.98万
-
财政年份:1998
-
负责人:APRILE L PILON
-
依托单位:
UBIQUITIN FUSION FOR PEPTIDE IMMUNE DISPLAY AND VACCINES
-
批准号:2076869
-
项目类别:
-
资助金额:$8.9万
-
财政年份:1996
-
负责人:APRILE L PILON
-
依托单位:
海外基金